These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16966542)

  • 1. Are initial demyelinating event recovery and time to second event under differential control?
    West T; Wyatt M; High A; Bostrom A; Waubant E
    Neurology; 2006 Sep; 67(5):809-13. PubMed ID: 16966542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K; Walsh C; Antonelli G; Hutchinson M
    Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?
    Chabas D; Castillo-Trivino T; Mowry EM; Strober JB; Glenn OA; Waubant E
    Neurology; 2008 Sep; 71(14):1090-3. PubMed ID: 18824673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate, degree, and predictors of recovery from disability following ischemic stroke.
    Hankey GJ; Spiesser J; Hakimi Z; Bego G; Carita P; Gabriel S
    Neurology; 2007 May; 68(19):1583-7. PubMed ID: 17485645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse severity and recovery in early pediatric multiple sclerosis.
    Fay AJ; Mowry EM; Strober J; Waubant E
    Mult Scler; 2012 Jul; 18(7):1008-12. PubMed ID: 22183939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability and prognosis of relapsing remitting multiple sclerosis, is it different in Iraqi patients?
    Hasan ZN
    Neurosciences (Riyadh); 2011 Jul; 16(3):233-6. PubMed ID: 21677613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P; Beyerle A; Ziemann U
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.